Pozen looking to US submission in 2H 2012 for secondary CV prevention drug
This article was originally published in Scrip
US company Pozen said it is working towards a US submission for its investigational oral product, PA32540, for the secondary prevention of cardiovascular disease, in the second half of next year, and will seek one or more strategic partners to "maximise the sales potential of PA32540 both in the US and globally".
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.